{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T08:19:15Z","timestamp":1783585155245,"version":"3.55.0"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The role of angiogenesis inhibitors in breast cancer (BC) remains unclear. Potential synergistic activity is observed between antiangiogenic tyrosine kinase inhibitors and cyclin-dependent kinase 4\/6 inhibitors. This trial evaluated the feasibility of combining the angiogenesis-targeting tyrosine kinase inhibitor famitinib with the cyclin-dependent kinase 4\/6 inhibitor dalpiciclib in patients with hormone receptor-positive human epidermal growth factor receptor 2-negative (HR+\/HER2\u2212) BC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Patients with HR+\/HER2\u2212 advanced BC were enrolled and treated with famitinib and dalpiciclib in combination with fulvestrant. A phase Ib dose-escalation study using a standard 3+3 design was conducted to determine the recommended phase II dose (RP2D). Phase II subsequently assessed the efficacy and safety of the RP2D. Exploratory biomarker analyses were performed to evaluate key gene mutations associated with this BC subtype, including\n                      <jats:italic toggle=\"yes\">PIK3CA<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">BRCA1\/2<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Based on dose-limiting toxicities and preliminary efficacy, daily famitinib 10 mg combined with dalpiciclib 100 mg plus fulvestrant was selected as the RP2D. An additional 28 patients were enrolled in phase II. The confirmed objective response rate (ORR) was 51.9% (95% confidence interval [CI]: 32.0%\u201371.3%), with a median progression-free survival (PFS) of 15.7 (95% CI: 7.3\u201325.4) months. The 2-year overall survival rate was 96.3% (95% CI: 76.5%\u201399.5%). Comparable ORRs and median PFS were observed regardless of\n                      <jats:italic toggle=\"yes\">PIK3CA<\/jats:italic>\n                      or\n                      <jats:italic toggle=\"yes\">BRCA1\/2<\/jats:italic>\n                      mutation status. Treatment-related adverse events of grade \u22653 were predominantly hematologic, including decreased neutrophil count (96.4%), decreased leukocyte count (75.0%), and decreased platelet count (10.7%). Patient enrollment was terminated after a comprehensive assessment of the benefit\u2013risk profile of this regimen.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Although the objective response threshold in the first stage of phase II was met, the median PFS did not demonstrate superiority over standard front-line regimens for HR+\/HER2\u2212 advanced BC, and overlapping hematologic toxicities were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov (NCT05176080) and Chictr.org.cn (ChiCTR2100053950)<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000004191","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T08:00:09Z","timestamp":1783584009000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Addition of angiogenesis inhibitors to CDK4\/6 inhibitors and fulvestrant in hormone receptor-positive, HER2-negative advanced breast cancer"],"prefix":"10.1097","author":[{"given":"Mengwei","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Breast Disease, Henan Breast Cancer Center\/The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan 450003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Breast Disease, Henan Breast Cancer Center\/The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan 450003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Lyu","sequence":"additional","affiliation":[{"name":"Department of Breast Disease, Henan Breast Cancer Center\/The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan 450003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Breast Disease, Henan Breast Cancer Center\/The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan 450003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiai","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Breast Disease, Henan Breast Cancer Center\/The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan 450003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenduo","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Breast Disease, Henan Breast Cancer Center\/The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan 450003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuchun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Breast Disease, Henan Breast Cancer Center\/The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan 450003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghua","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Breast Disease, Henan Breast Cancer Center\/The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan 450003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Breast Disease, Henan Breast Cancer Center\/The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan 450003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Breast Disease, Henan Breast Cancer Center\/The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan 450003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Breast Disease, Henan Breast Cancer Center\/The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan 450003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Breast Disease, Henan Breast Cancer Center\/The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan 450003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajing","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Breast Disease, Henan Breast Cancer Center\/The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan 450003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Breast Disease, Henan Breast Cancer Center\/The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan 450003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"R1-20260709","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/CM9.0000000000003921","article-title":"Global burden and trends of breast cancer: GLOBOCAN 2022 estimates of incidence and mortality in 185 countries","volume":"139","author":"Gu","year":"2025","journal-title":"Chin Med J (Engl)"},{"key":"R2-20260709","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1097\/CM9.0000000000003442","article-title":"Comparative analysis of cancer statistics in China and the United States in 2024","volume":"137","author":"Wu","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"R3-20260709","first-page":"480","article-title":"Systemic therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer","volume":"73","author":"Huppert","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R4-20260709","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S0140-6736(04)16981-X","article-title":"Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: Long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials","volume":"364","author":"Fisher","year":"2004","journal-title":"Lancet"},{"key":"R5-20260709","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1056\/NEJM198902233200802","article-title":"A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors","volume":"320","author":"Fisher","year":"1989","journal-title":"N Engl J Med"},{"key":"R6-20260709","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.2004.09.070","article-title":"Ten-Year Outcomes in a Population-Based Cohort of Node-Negative, Lymphatic, and Vascular Invasion\u2013Negative Early Breast Cancers Without Adjuvant Systemic Therapies","volume":"22","author":"Chia","year":"2004","journal-title":"J Clin Oncol"},{"key":"R7-20260709","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and Letrozole in Advanced Breast Cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"R8-20260709","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"key":"R9-20260709","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"key":"R10-20260709","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.7150\/jca.44313","article-title":"Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment","volume":"11","author":"Madu","year":"2020","journal-title":"J Cancer"},{"key":"R11-20260709","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21186708","article-title":"Intra-Tumoral Angiogenesis Is Associated with Inflammation, Immune Reaction and Metastatic Recurrence in Breast Cancer","volume":"21","author":"Oshi","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R12-20260709","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1200\/JCO.2010.34.1255","article-title":"RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"29","author":"Brufsky","year":"2011","journal-title":"J Clin Oncol"},{"key":"R13-20260709","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","article-title":"Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"28","author":"Miles","year":"2010","journal-title":"J Clin Oncol"},{"key":"R14-20260709","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"R15-20260709","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","article-title":"RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer","volume":"29","author":"Robert","year":"2011","journal-title":"J Clin Oncol"},{"key":"R16-20260709","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1158\/1078-0432.CCR-21-4179","article-title":"Phase Ib\/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer","volume":"28","author":"Lim","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R17-20260709","doi-asserted-by":"crossref","first-page":"533","DOI":"10.21873\/cdp.10138","article-title":"Effect of Bevacizumab on a Human Breast Cancer Model that Exhibited Palbociclib-resistance by RB Knockout","volume":"2","author":"Ishikura","year":"2022","journal-title":"Cancer Diagn Progn"},{"key":"R18-20260709","doi-asserted-by":"crossref","DOI":"10.3390\/cells10113008","article-title":"FGFR1 Overexpression Induces Cancer Cell Stemness and Enhanced Akt\/Erk-ER Signaling to Promote Palbociclib Resistance in Luminal A Breast Cancer Cells","volume":"10","author":"Cheng","year":"2021","journal-title":"Cells"},{"key":"R19-20260709","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s41467-019-09068-2","article-title":"Aberrant FGFR signaling mediates resistance to CDK4\/6 inhibitors in ER+ breast cancer","volume":"10","author":"Formisano","year":"2019","journal-title":"Nat Commun"},{"key":"R20-20260709","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.7150\/jca.26068","article-title":"Antitumor activity of sorafenib plus CDK4\/6 inhibitor in pancreatic patient derived cell with KRAS mutation","volume":"9","author":"Lee","year":"2018","journal-title":"J Cancer"},{"key":"R21-20260709","doi-asserted-by":"crossref","first-page":"95116","DOI":"10.18632\/oncotarget.19618","article-title":"The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors","volume":"8","author":"Small","year":"2017","journal-title":"Oncotarget"},{"key":"R22-20260709","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215665","article-title":"Palbociclib in combination with sunitinib exerts a synergistic anti-cancer effect in patient-derived xenograft models of various human cancers types","volume":"536","author":"Moskovits","year":"2022","journal-title":"Cancer Lett"},{"key":"R23-20260709","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.563249","article-title":"Simultaneous Combination of the CDK4\/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines","volume":"10","author":"Digiacomo","year":"2020","journal-title":"Front Oncol"},{"key":"R24-20260709","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.942341","article-title":"CDK4\/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells","volume":"12","author":"Digiacomo","year":"2022","journal-title":"Front Oncol"},{"key":"R25-20260709","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS20-PD1-03","article-title":"Abstract PD1-03: A phase Ib trial of fulvestrant + CDK4\/6 inhibitor (CDK4\/6i) palbociclib + pan-FGFR tyrosine kinase inhibitor (TKI) erdafitinib in FGFR-amplified\/ ER+\/ HER2-negative metastatic breast cancer (MBC)","volume":"81","author":"Mayer","year":"2021","journal-title":"Cancer Research"},{"key":"R26-20260709","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00280-013-2282-y","article-title":"Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib","volume":"72","author":"Zhou","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"R27-20260709","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00280-014-2505-x","article-title":"Hypothyroidism as a potential biomarker of efficacy of famitinib, a novel VEGFR-2 inhibitor in metastatic breast cancer","volume":"74","author":"Cao","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"R28-20260709","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1158\/1078-0432.CCR-21-4313","article-title":"Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial","volume":"28","author":"Chen","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R29-20260709","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol"},{"key":"R30-20260709","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S1470-2045(23)00172-9","article-title":"Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"24","author":"Zhang","year":"2023","journal-title":"Lancet Oncol"},{"key":"R31-20260709","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1001\/jamaoncol.2021.4301","article-title":"Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial","volume":"7","author":"Llombart-Cussac","year":"2021","journal-title":"JAMA Oncol"},{"key":"R32-20260709","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/s41591-021-01562-9","article-title":"Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial","volume":"27","author":"Xu","year":"2021","journal-title":"Nat Med"},{"key":"R33-20260709","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"key":"R34-20260709","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+\/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol"},{"key":"R35-20260709","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1477-7800-4-22","article-title":"Quantification of angiogenesis in estrogen receptor-positive and negative breast carcinoma","volume":"4","author":"Parentes-Vieira","year":"2007","journal-title":"International Seminars in Surgical Oncology"},{"key":"R36-20260709","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1200\/JCO.2011.40.2305","article-title":"Paclitaxel, not bevacizumab, was primarily responsible for the favorable effects seen in the RIBBON-2 trial","volume":"30","author":"Kesikli","year":"2012","journal-title":"J Clin Oncol"},{"key":"R37-20260709","article-title":"Endocrine Resistance Score Based on Three Key Genes Predicts Prognosis and Reveals Potential Therapeutic Targets for ER+HER2- Breast Cancer","author":"Ping","year":"2025","journal-title":"Cell Prolif"},{"key":"R38-20260709","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"key":"R39-20260709","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2147\/CLEP.S206949","article-title":"A systematic review of the international prevalence of BRCA mutation in breast cancer","volume":"11","author":"Armstrong","year":"2019","journal-title":"Clin Epidemiol"},{"key":"R40-20260709","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"key":"R41-20260709","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1186\/s12885-022-10078-5","article-title":"PIK3CA mutation status, progression and survival in advanced HR\u2009+\u2009\/HER2- breast cancer: a meta-analysis of published clinical trials","volume":"22","author":"Fillbrunn","year":"2022","journal-title":"BMC Cancer"},{"key":"R42-20260709","doi-asserted-by":"crossref","first-page":"e2400841","DOI":"10.1200\/PO-24-00841","article-title":"Impact of BRCA Mutation on Treatment Outcomes of Endocrine Therapy \u00b1 CDK4\/6 Inhibitors in Hormone Receptor-Positive\/Human Epidermal Growth Factor Receptor-2-Negative Breast Cancer: A Systematic Review and Meta-Analysis","volume":"9","author":"Azim","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"R43-20260709","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N Engl J Med"},{"key":"R44-20260709","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104544","article-title":"Impact of germline BRCA1\/2 status on outcomes for patients with HR+\/HER2- metastatic breast cancer treated with CDK4\/6 inhibitors: a systematic review and meta-analysis","volume":"83","author":"Bottosso","year":"2025","journal-title":"Breast"},{"key":"R45-20260709","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1111\/bph.12047","article-title":"Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients","volume":"168","author":"Xie","year":"2013","journal-title":"Br J Pharmacol"},{"key":"R46-20260709","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40364-021-00271-2","article-title":"A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4\/6 inhibitor in Chinese patients with advanced breast cancer","volume":"9","author":"Zhang","year":"2021","journal-title":"Biomark Res"},{"key":"R47-20260709","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/17425255.2023.2292112","article-title":"CYP3A inhibitor itraconazole affect pharmacokinetic behavior of famitinib and its active metabolite: results of a single-center, single-arm, open-label and fixed sequence study","volume":"19","author":"Huang","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000004191","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T08:00:16Z","timestamp":1783584016000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000004191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":47,"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000004191","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"2025-12-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}